Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2005

View Archived Issues

FK-228 investigated in phase I and phase II oncology trials

Study data reveal efficacy of zileuton in moderate to severe asthma

Altachem updates restructuring progress

Enrollment completed in phase IIb study of valopicitabine for hepatitis C

Biovitrum and Karolinska Institutet collaborate on inflammation research

Renovis and Pfizer establish VR1 antagonist collaboration

Phase I/II prostate cancer study of SPI-153 gets green light

4SC receives funding to develop new MS drug candidates

Tarvacin cleared to enter phase I study for HCV

New treatments claimed for Alzheimer's disease and other neurological disorders

Toxicity studies commence with ARQ-197

Phase I trial for Novagali's oral formulation of paclitaxel

Fast track designation for Riquent

First stage completed in phase IIa study of ATL-104 for mucositis

BioXell signs TREM development agreement with Merck

IND approval for cholesterol drug MAHDL-01

Phase I data on the immunogenicity and safety of the AMA1-C1 malaria vaccine

AD-237 reported safe and effective in improving lung function of COPD patients

A new clinical trial to assess the benefits of tolvaptan in heart failure / News in Context

Recent patents describe novel treatments for osteoporosis

NitroMed reports novel agents for treating cardiovascular diseases

Good safety and immunogenicity results reported for the Shigella vaccine CVD-1208S

FDA approval for Naglazyme

Update on sitaxsentan in pulmonary arterial hypertension

New phase I data on the effects and safety of ChimeriVax-West Nile vaccine

Promising alternative to gemcitabine offered by 4-thio-FAC

Enbrel approved to improve physical function in psoriatic arthritis

Derivatives of human embryonic stem cells offer potential for recovery after spinal cord injury

Prous Science's LifeSciChannel.com webcasts the AUA 2005 Annual Meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...